Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CLN-049 |
Synonyms | |
Therapy Description |
CLN-049 is a bispecific antibody that targets FLT3 and CD3, potentially inducing activation of CD4- and CD8-positive T cells and inhibiting tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2078). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CLN-049 | CLN049|CLN 049 | CD3 Antibody 103 FLT3 Antibody 5 | CLN-049 is a bispecific antibody that targets FLT3 and CD3, potentially inducing activation of CD4- and CD8-positive T cells and inhibiting tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2078). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 positive | acute myeloid leukemia | predicted - sensitive | CLN-049 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CLN-049 decreased growth and increased survival in a cell line xenograft model of FLT3-positive acute myeloid leukemia (Cancer Res 2022;82(12_Suppl):Abstract nr 2078). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05143996 | Phase I | CLN-049 | CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) | Recruiting | USA | 0 |